Matthew Wiley Net Worth

The estimated Net Worth of Matthew T. Wiley is at least $5.05 millier dollars as of 15 June 2024. Mr. Wiley owns over 750 units of Menlo Therapeutics stock worth over $5,052 and over the last 6 years he sold MNLO stock worth over $0. In addition, he makes $0 as Chief Commercial Officer at Menlo Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Wiley MNLO stock SEC Form 4 insiders trading

Matthew has made over 3 trades of the Menlo Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 750 units of MNLO stock worth $1,013 on 15 June 2024.

The largest trade he's ever made was buying 13,440 units of Menlo Therapeutics stock on 5 March 2019 worth over $50,534. On average, Matthew trades about 1,074 units every 121 days since 2018. As of 15 June 2024 he still owns at least 3,742 units of Menlo Therapeutics stock.

You can see the complete history of Mr. Wiley stock trades at the bottom of the page.

Matthew Wiley biography

Matthew T. Wiley serves as Chief Commercial Officer of the Company. From November 2018 until the Closing Date, Mr. Wiley served as the Chief Commercial Officer of Foamix. Mr. Wiley has more than 20 years of commercial experience across a broad range of specialty pharmaceutical categories. Prior to joining Foamix, Mr. Wiley held several positions of increasing responsibility at Jazz Pharmaceuticals from 2012 to 2018, including as Vice President of Marketing and Business Unit Lead for the company’s sleep disorder portfolio. He holds a B.A. in English from Syracuse University.

How old is Matthew Wiley?

Matthew Wiley is 48, he's been the Chief Commercial Officer of Menlo Therapeutics since 2020. There are 8 older and 1 younger executives at Menlo Therapeutics. The oldest executive at Menlo Therapeutics, Inc. is Rex Bright, 79, who is the Director.

What's Matthew Wiley's mailing address?

Matthew's mailing address filed with the SEC is Rehovot, Israel.

Insiders trading at Menlo Therapeutics

Over the last 7 years, insiders at Menlo Therapeutics have traded over $3,825,000 worth of Menlo Therapeutics stock and bought 3,655,938 units worth $21,205,011 . The most active insiders traders include Advisors Llcperceptive Life..., Llc Fmr et Albert Cha. On average, Menlo Therapeutics executives and independent directors trade stock every 85 days with the average trade being worth of $572,944. The most recent stock trade was executed by Sharon Barbari on 20 August 2020, trading 75,000 units of MNLO stock currently worth $111,000.

What does Menlo Therapeutics do?

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.

Complete history of Mr. Wiley stock trades at Menlo Therapeutics et BioXcel Therapeutics Inc

Menlo Therapeutics executives and stock owners

Menlo Therapeutics executives and other stock owners filed with the SEC include:

• Elisabeth Sandoval,
  Independent Director
• Patrick LePore,
  Independent Director
• Anthony Bruno,
  Director
• Rex Bright,
  Director
• Sharon Barbari,
  Director
• Matthew Wiley,
  Chief Commercial Officer
• Mutya Harsch,
  Chief Legal Officer, General Counsel
• Ronald Krasnow,
  Chief Compliance Officer
• Iain Stuart,
  Chief Scientific Officer
• Andrew Saik,
  Chief Financial Officer, Treasurer
• David Domzalski,
  Chief Executive Officer, Director
• Steven L Basta,
  Director
• Advisors Llcperceptive Life...,
  
• Ilan Hadar,
  CFO and Country Manager
• Stanley Hirsch,
  Director
• Partners 2007 Gp, L.P.Presi...,
  
• Global Strategic Fund Ii L....,
  10% owner
• Ventures Llc Remeditex,
  10% owner
• Capital Viii, Llc Vivo Capi...,
  
• Albert Cha,
  Director
• Llc Fmr,
  
• Scott M Whitcup,
  Director
• Mary Spellman,
  Chief Medical Officer
• Kristine M Ball,
  See Remarks
• David W J Mcgirr,
  Director
• Paul L Berns,
  Director
• Ted Ebel,
  Director
• Aaron Royston,
  Director
• Paul Kwon,
  Chief Scientific Officer